Curcumin
Curcumin (Curcuma longa diferuloylmethane)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Turmeric extract, Diferuloylmethane, Curcumin phytosome, Meriva, Theracurmin
103 randomised trials across 42 outcomes, with high-certainty evidence for four of them, including CRP. Absorption is the whole problem, so the evidence belongs to specific formulations rather than to turmeric.
Overview
Curcumin has one of the largest randomised literatures of any plant compound, and reading it requires separating three things that get conflated: turmeric the spice, curcumin the molecule, and the specific enhanced-absorption formulations that trials actually use.
A 2024 review pooled 103 randomised trials in 7,216 participants across 42 outcomes. Roughly 55% of outcomes were statistically significant, and the evidence was rated high certainty for exactly four: fasting blood sugar, C-reactive protein, HDL and weight. Everything else was moderate, low or very low. A separate GRADE-assessed analysis of 66 trials found CRP down 0.58 mg/L, TNF-alpha and IL-6 both reduced, and IL-1 beta unchanged.
So curcumin measurably lowers inflammatory markers. Whether lowering them changes how anyone's life goes is not what these trials measured.
Mechanism of action
Curcumin is a polyphenol that interacts with a very large number of molecular targets, which is both its appeal and a reason for caution, since promiscuous binding in vitro often does not translate. The best-supported actions are inhibition of NF-kappa-B signalling, which reduces transcription of inflammatory cytokines, and Nrf2 activation raising endogenous antioxidant enzyme expression. Its central pharmacological problem is bioavailability: plain curcumin is poorly absorbed, rapidly glucuronidated and sulfated in the intestine and liver, and cleared fast. Every commercial strategy, piperine co-administration, phytosome complexes, nanoparticle and micellar formulations, exists to solve that, and each produces different plasma exposure.
Human evidence
Large randomised base with consistent effects on inflammatory and metabolic markers. High-certainty evidence exists for four outcomes out of 42, and no trial has measured a hard clinical event.
- 103 randomised trials, 7,216 participants: high certainty for fasting blood sugar, CRP, HDL and weight. Everything else moderate or worse.
- 66 trials pooled for inflammation: CRP down 0.58 mg/L, TNF-alpha and IL-6 both down, IL-1 beta unchanged.
- The inconsistent findings cluster where absorption differs, which is what you would expect if formulation drives exposure and exposure drives effect.
- Osteoarthritis symptom trials are among the more positive clinical applications, with effect sizes modest and comparators often active rather than placebo.
- Safety across this literature is good at supplement doses, with gastrointestinal complaints the usual adverse effect. Rare hepatotoxicity has been reported with high-dose enhanced-absorption products.
What this does not tell you: Two limits dominate. First, almost every endpoint is a biomarker. Lowering CRP by 0.58 mg/L is a measurable change in a number that predicts risk; no curcumin trial has shown that lowering it this way prevents anything. Second, the evidence attaches to formulations rather than to the molecule. A trial of a phytosome complex says little about a plain turmeric capsule, and nothing about turmeric in food, where curcuminoid content is only 2 to 5%. The 2024 review's own authors flag methodological quality across the included studies as a limitation.
Reading the research record
Curcumin is the cleanest example in this pillar of a compound whose evidence is real but attached to the wrong thing. A reader who sees 103 randomised trials reasonably concludes that curcumin is well studied, and it is. What the number hides is that only four of 42 outcomes reached high certainty, and that the trials used specific engineered formulations chosen to solve an absorption problem that a spice jar does not solve.
That matters practically. If you are taking curcumin because your CRP is up, the trials support a formulation with demonstrated absorption, at a trial dose, with a retest of CRP to tell you whether it worked for you. If you are taking turmeric powder in food for the same reason, you are doing something the literature has not tested.
The evidence, charted
Fig. 1 · evidence composition
0of 3 citations (0%) are in people
Every citation cited here is Review work; no other study type is cited on this page. This count is of our own citation list and understates any literature larger than the sources we cite.
Fig. 2 · evidence over time
Citations here span just two years, 2023 and 2024.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Review2024
Curcumin on human health: a comprehensive systematic review and meta-analysis of 103 randomized controlled trials
103 randomised trials, 7,216 participants, 42 outcomes. 23 of 42 outcomes were statistically significant. Certainty was rated high for only four: fasting blood sugar, C-reactive protein, HDL and weight. Ten outcomes were moderate, 14 low and 14 very low. The authors note limitations in the methodological quality of the included studies.
Phytotherapy Research - Review2023
Antioxidant and anti-inflammatory effects of curcumin/turmeric supplementation in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials
66 randomised trials. CRP down 0.58 mg/L (95% CI minus 0.74 to minus 0.41), TNF-alpha down 3.48 pg/mL and IL-6 down 1.31 pg/mL. IL-1 beta was unchanged at minus 0.46 pg/mL (95% CI minus 1.18 to 0.27). Antioxidant markers improved.
Cytokine - Review2023
Effect of curcumin on rheumatoid arthritis: a systematic review and meta-analysis
The closest this literature comes to a clinical rather than biochemical endpoint, in a defined inflammatory disease. Included because it is a symptom and disease-activity analysis rather than a marker analysis.
Frontiers in Immunology
Frequently asked questions
Is turmeric the same as curcumin?
No, and the difference is large enough to matter. Turmeric root is roughly 2 to 5% curcuminoids, and curcumin on its own absorbs poorly. Trials use enhanced-absorption formulations, with piperine, phytosome complexes or nanoparticles, precisely because plain curcumin barely reaches the bloodstream.
Does it actually reduce inflammation?
It reduces inflammatory markers, reliably. Across 66 randomised trials CRP fell by 0.58 mg/L, with TNF-alpha and IL-6 also down and IL-1 beta unchanged. Whether that change prevents any disease is a separate question no trial has answered.
Which formulation should I use?
One that a trial used. Because absorption is the limiting factor and each strategy produces different plasma exposure, evidence does not transfer freely between products. This is the case where matching the product to the study is not fussiness, it is the whole thing.
Is it safe?
At supplement doses, generally yes, with stomach upset the common complaint. Rare liver injury has been reported with high-dose enhanced-absorption products, which is a reminder that improving the absorption of a compound also improves the absorption of its risks.
Latest reading on Curcumin
Articles from the blog that cover Curcumin, newest first.